rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
PA and GG BRAF V600E-mutant had significantly lower rADCmean (p < 0.001) and rADCmin (p < 0.001) values than wild type, regardless of tumor histology and location.
|
31667545 |
2020 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Half of the tumors in our patient cohort were V600-wildtype and half were V600E mutant.All tumors expressed PD-L1.
|
31819973 |
2020 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We then knocked a mutation into BRAF encoding the V600E substitution and overexpressed the GREM1 transgene; the organoids were transplanted into colons of NOG mice and growth of xenograft tumors was measured.
|
31622618 |
2020 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
|
31672130 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We analyzed mutations of BRAF (V600E) and TERT promoter (C228T, C250T) in tumor DNA from 141 patients (75 with classical variant PTC, CVPTC; 66 with follicular variant PTC, FVPTC) recruited through a multi-center study.
|
31454788 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In addition, we identified a subset of BRAF(V600E) tumors that were resistant to the combined treatment, in which FGFR was found to drive feedback-induced RAS activation, independently of SHP2.
|
30605687 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF V600E and SRC mutations were mutually exclusive, and SRC mutation was significantly associated with left-sided tumor and liver metastasis compared to BRAF V600E mutation (P = 0.016 and P = 0.025, respectively).
|
30792536 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this scenario, we simulated and analyzed the dynamics of BRAF V600E melanoma patients treated with BRAF inhibitors in order to find potentially interesting targets that may make standard treatments more effective in particularly aggressive tumors that may not respond to selective inhibitor drugs.
|
28767374 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The presence of BRAF-V600E mutations in ameloblastoma was related to decreased levels of glycerol in comparison with tumors carrying only wild-type alleles of this gene.
|
30739334 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Application of the IHC VE1 assay was highly feasible in primary/metastatic sites or effusion blocks, yielding positive findings in 28 of 29 (96.6%) <i>BRAF</i> V600E-mutated tumors and negative results in 69 of 70 (98.6%) tumors harboring other types or undetected mutations.
|
31234388 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The association between clinical-pathologic features and BRAF V600E mutation in ameloblastomas may provide directions for the treatment of this neoplasia.
|
29855709 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Coexisting BRAF V600E and TERT hotspot promoter mutations were detected in 9.5% (54/568) of patients, and significantly associated with older patient age (P = 0.001), gross extrathyroidal extension (P = 0.003), tumor stage pT3-4 (P = 0.005), stage II to IV (P = 0.019), intermediate or high initial risk (P = 0.003), worse than excellent response to primary therapy (P = 0.045), recurrence (P = 0.015), and final outcome of no remission (P = 0.014).
|
31305897 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Overall, SATB2-negative and/or CDX2-negative expression was identified in 33% of mismatch repair protein deficient tumors compared with only 15% of mismatch repair protein proficient tumors (p < 0.001) and in 36% of BRAF V600E mutated compared with only 13% of BRAF wild-type tumors (p < 0.001).
|
30962505 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A molecular screening of the tumor revealed a BRAF V600E mutation.
|
31781502 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Whole exome and transcriptome sequencing revealed a high mutational burden tumor (22 mutations/Megabase) with homozygous BRAF V600E mutation.
|
30264293 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Dual mitogen-activated protein kinase (MAPK) pathway inhibition of BRAF V600E/K and MEK 1/2 kinases with BRAF-MEK inhibitors using dabrafenib-trametinib, vemurafenib-cobimetinib and encorafenib-binimetinib is now the standard of care for BRAF V600E/K tumours.
|
30868471 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Tumor immunohistochemical (IHC) MMR for protein expression and microsatellite instability (MSI) status were evaluated, and in those with loss of MLH1 expression by IHC, somatic BRAF V600E mutation and both somatic and germline MLH1 methylation levels were studied.
|
30693488 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Specifically, the "BRAF-like" subtype was enriched in invasive FV-PTCs and tumors with BRAF V600E mutations.
|
30645670 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF V600E was found to influence the composition of the so-called tumour microenvironment modulating both solid (immune-cell infiltration) and soluble (chemokines) mediators, which balance characterize the ultimate behaviour of the tumour, making it more or less aggressive.
|
31762942 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In the present report we describe a BRAF V600E-mutated tumor with divergent morphological appearance comprising of anaplastic pleomorphic xanthoastrocytoma and astroblastoma.
|
30557911 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Additionally, an analysis of the correlation network reconstructed using TCGA-SKCM emphasized KMO and KYNU with high variability among BRAF wild-type compared with V600E, which underscored their role in distinct CD4+ T-cell behavior in tumour immunity.
|
31434983 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Using the BRAF mutation 1799T>A to separate the response of tumor and non-tumor cells to a drug, such as vemurafenib, is feasible, supporting a foundation for a genetic in vitro tool for testing drug efficacy and specificity.
|
30952717 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and Mutation-specific Immunohistochemistry.
|
29271794 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Moreover, a 47-year-old female with a recurrent adenocarcinoma and a BRAF V600E mutation exhibited tumor regression after a fourth line therapy with dabrafenib and trametinib, targeting agents against BRAF mutations.
|
31440061 |
2019 |
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
All the tumors were IDH wild-type, BRAF (V600E)-immunonegative and unmethylated for MGMT promoter.
|
30937985 |
2019 |